Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Gene Mutations”

408 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 408 results

Testing effectiveness (Phase 2)Study completedNCT03046992
What this trial is testing

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Gene Mutation
Yuhan Corporation 224
Testing effectiveness (Phase 2)Study completedNCT01204307
What this trial is testing

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Who this might be right for
Advanced Non-Squamous Non-Small Cell Lung Cancer
Chang Gung Memorial Hospital 101
Early research (Phase 1)Looking for participantsNCT06816992
What this trial is testing

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Who this might be right for
Solid TumorsEGFR Exon 20 Insertion MutationsNSCLC+1 more
ORIC Pharmaceuticals 76
Testing effectiveness (Phase 2)Study completedNCT00588445
What this trial is testing

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Who this might be right for
Lung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer
Memorial Sloan Kettering Cancer Center 65
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Not applicableUnknownNCT03236675
What this trial is testing

Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Exosome Diagnostics, Inc. 60
Not applicableUnknownNCT02661009
What this trial is testing

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Who this might be right for
Non Small Cell Lung CancerEGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation
GenoSaber 1,000
Not applicableUnknownNCT03071705
What this trial is testing

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small Cell AdenocarcinomaTyrosine Kinase MutationEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico 120
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Not applicableStudy completedNCT00717002
What this trial is testing

Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study

Who this might be right for
Non Small Cell Lung Cancer
National University Hospital, Singapore
Not applicableApproved For MarketingNCT04535557
What this trial is testing

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Millennium Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)UnknownNCT05277701
What this trial is testing

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations

Who this might be right for
NSCLC
Yonsei University 36
Large-scale testing (Phase 3)Not Yet RecruitingNCT06323148
What this trial is testing

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Who this might be right for
Lung CancerEGFR Gene MutationMinimal Residual Disease
Fudan University 226
Testing effectiveness (Phase 2)UnknownNCT01410214
What this trial is testing

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer Stage IIIA
Chinese Lung Cancer Surgical Group 80
Testing effectiveness (Phase 2)Looking for participantsNCT07117890
What this trial is testing

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Who this might be right for
Non Small Cell Lung Cancer
Fudan University 34
Testing effectiveness (Phase 2)UnknownNCT02037997
What this trial is testing

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Fudan University 80
Large-scale testing (Phase 3)UnknownNCT01405079
What this trial is testing

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 222
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Testing effectiveness (Phase 2)Looking for participantsNCT03191149
What this trial is testing

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI) 46
Testing effectiveness (Phase 2)Ended earlyNCT04172597
What this trial is testing

Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Who this might be right for
Breast CancerColorectal CancerSolid Tumor+1 more
Spectrum Pharmaceuticals, Inc 1
Next Page